Publications

Avicenna Alliance Executive Summary - The role of Artificial Intelligence within in silico medicine

Members of the Avicenna Alliance were eager to provide feedback the European Commission’s White Paper on artificial intelligence and therefore started working on an Avicenna Alliance white paper on ‘’the role of artificial intelligence within in silico medicine”. Given the great interest shown by the members of the Alliance and the time necessary to respond to the European Commission's public consultation on AI, it was decided to produce a provisional executive summary on “The role of Artificial Intelligence within in silico medicine “ as an introduction to the white paper to be published later in 2020 to provide feedback to the European Commission.

Avicenna Alliance Position Paper - AI and Big Data effective readiness: A privacy-enhancing pathway to data access

The Avicenna Alliance warmly welcomes the European Commission’s ambitious policy package, including the European strategy for data and the White Paper on artificial intelligence aimed at making the EU fit for the digital age. In particular, the Avicenna Alliance Members welcome the European Commission’s Data Strategy and its various references to the promising opportunities brought by health data for personalised medicine and the benefits and advances that computer modelling and simulation technologies can bring in healthcare.

To make the best of the new EU strategy, the Members of the Avicenna Alliance have drafted this position paper which applies both to the Public Consultations on a European Strategy for Data and the White Paper on Artificial Intelligence. This document has been developed by members of the Avicenna Alliance from medtech, pharmaceutical, software and...

Avicenna Alliance Members Case Studies on in silico medicine

What can CM&S accomplish? Nothing short of redefining terms like ‘patient safety’, ‘efficacy’ and ‘cost effectiveness’ by forever raising the quality of data needed to meet high standards.

To do this we need to demonstrate what can be already done to give an idea of what we could do in future with the right regulator support and uptake across the healthcare sector.

The case studies in this document give but a glimpse of the potential that has yet to be unleashed by modelling and simulation.

Avicenna Alliance White Paper - Modelling And Simulation As A Transformative Tool for Medical Devices: The Transatlantic Regulatory Landscape

This White Paper highlights the potential of computer modelling and simulation in medtech and the regulatory and political barriers to unlocking that full potential.

Developed by Members of the Avicenna Alliance from the Medtech and Software sectors as well as the FDA, this paper is the starting point for a much needed discussion on how the policy framework governing the healthcare sector can be reformed to adapt to the technologies of the digital age that can in turn be put to use to solve some of the greatest healthcare challenges facing society.

This paper was official launched in the European Parliament on 04 September 2018 and is addressed to policy makers and regulators familiar with existing EU regulatory structures as well as those experienced in the medtech or software spheres.

In silico medicine in Europe

The undersigned, in their capacity as representatives of the VPH Institute, and of the Discipulus, INBIOMEDvision, PHS Foresight, CaSyM, and Avicenna support actions funded by the European Commission in the domain of in silico medicine, as well as the IMI-eTRIKS Consortium agreed to release the following joint statement: The use of information technology in healthcare is progressively expanding from its initial role of managing administrative information into that of support for the provision of care, whether related to prevention, diagnosis, prognosis, or treatment … 

Data Protection Regulation

On 12 March 2014, the European Parliament voted on its position on the new European Union (EU) proposal for a General Data Protection Regulation, which will be now negotiated among the European Parliament, the Council of the European Union and the European Commission [1]. The final text will set the rules under which personal data are to be handled in the EU. It will thus affect many areas of our everyday life, including health and research. The cancer community is deeply concerned about unintended consequences of the current wording of the draft Regulation [2], which may put at stake the survival of retrospective clinical research, biobanking, and populationbased cancer registries in the EU …